(Q38047084)

27 August 2017

Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation (English)

1 reference

27 August 2017

0 references

Paul D Griffiths

1

1 reference

27 August 2017

24 September 2012

1 reference

Lancet Infectious Diseases

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

10

1 reference

27 August 2017

790-798

1 reference

Isolation of Intranuclear Inclusion Producing Agents from Infants with Illnesses Resembling Cytomegalic Inclusion Disease

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

INFECTIOUS PULMONARY DISEASE IN PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY FOR ORGAN TRANSPLANTATION

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. II.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

The dynamics of human cytomegalovirus replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human Cytomegalovirus (HCMV) Replication Dynamics in HCMV‐Naive and ‐Experienced Immunocompromised Hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Acquisition of human cytomegalovirus infection in infants via breast milk: natural immunization or cause for concern?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Young children as a probable source of maternal and congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus Infection in a Day-Care Center

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Influence of sexual activity on cytomegalovirus seroprevalence in the United States, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

A prospective study of primary cytomegalovirus infection in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Maternal immunity and prevention of congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Salivary shedding of Epstein-Barr virus and cytomegalovirus in people infected or not by human immunodeficiency virus 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Washing our hands of the congenital cytomegalovirus disease epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Congenital cytomegalovirus (CMV) epidemiology and awareness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

CMV in critically ill patients: pathogen or bystander?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus and human immunosenescence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Role of cytomegalovirus in the T cell changes seen in elderly individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Amyloid: little proteins, big clues.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Interrelationships among Quantity of Human Cytomegalovirus (HCMV) DNA in Blood, Donor‐Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for HCMV Disease following Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination--an impact of immunosenescence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus sero positivity dramatically alters the maternal CD8+ T cell repertoire and leads to the accumulation of highly differentiated memory cells during human pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Encouraging prospects for immunisation against primary cytomegalovirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Incidence of cytomegalovirus infection among the general population and pregnant women in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Women's knowledge of congenital cytomegalovirus: results from the 2005 HealthStyles survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Genetic content of wild-type human cytomegalovirus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

T cells and viral persistence: lessons from diverse infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Update on the current status of cytomegalovirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Vaccine prevention of maternal cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus seroepidemiology in an urban community of São Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Modelling immunization strategies with cytomegalovirus vaccine candidates.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus blood viral load and hearing loss in young children with congenital infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Newborn Screening for Severe Combined Immunodeficiency; The Wisconsin Experience (2008–2011)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Impact of diagnostic and confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive cytomegalovirus immunoglobulin M antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Improved prenatal diagnosis of congenital human cytomegalovirus infection by a modified nested polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

10.1016/S1473-3099(12)70197-4

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23017365